Zepbound® providers &
prescriptions in Yuma, AZ
Verified Zepbound providers in Yuma, AZ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find a Zepbound provider in Arizona.
Every entry is checked against the NPI registry and the Arizona medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Zepbound in Yuma.
29 GLP-1 prescribers and 7 local resource types are on record for Yuma, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Arizona’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.
Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]
Community health · CDC
Weight & metabolic health in Yuma
Yuma, Arizona has a population of 95,548 people. The adult obesity rate in Yuma is an age-adjusted estimate of 38.1%, 4.8 percentage points above the Arizona state rate of 33.3%. Diagnosed diabetes reaches 12.4% of adults in Yuma. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 26.1% of adults in Yuma.
- of Yuma adults have obesity
- 38.1%
- diagnosed diabetes
- 12.4%
- no regular physical activity
- 26.1%
Age-adjusted estimates for Yuma, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Yuma.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Yuma, AZ, ordered as the registry lists them, never by who pays us.
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
1246 W 20Th Pl
250 W 24Th St Ste O
Fitness clubs and recreation centers
Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.
What the trials actually showed.
We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]